STOCK TITAN

[8-K] Sagimet Biosciences Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Sagimet Biosciences (SGMT) furnished an updated investor presentation as Exhibit 99.1 to a Form 8-K. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished and are not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth in a future filing.

Representatives may use the updated presentation in meetings with investors from time to time. The filing is an informational Reg FD update and does not announce a transaction or financial results.

Sagimet Biosciences (SGMT) ha fornito una presentazione aggiornata agli investitori come Exhibit 99.1 in un Form 8-K. L'azienda afferma che i materiali in Item 7.01 e Exhibit 99.1 sono forniti e non considerati depositati ai sensi della Sezione 18 della Exchange Act, né incorporati per riferimento se non espressamente indicato in un futuro deposito.

I rappresentanti possono utilizzare la presentazione aggiornata durante incontri con gli investitori di volta in volta. Il deposito è un aggiornamento informativo Reg FD e non annuncia una transazione o risultati finanziari.

Sagimet Biosciences (SGMT) proporcionó una presentación para inversores actualizada como el Exhibit 99.1 a un Formulario 8-K. La compañía declara que los materiales en el Item 7.01 y Exhibit 99.1 se están proporcionando y no se consideran presentados conforme a la Sección 18 de la Exchange Act, ni incorporados por referencia a menos que se indique expresamente en un depósito futuro.

Los representantes pueden utilizar la presentación actualizada en reuniones con inversores de vez en cuando. El depósito es una actualización informativa Reg FD y no anuncia una transacción ni resultados financieros.

Sagimet Biosciences (SGMT)는 Form 8-K의 Exhibit 99.1로 업데이트된 투자자 발표를 제공했습니다. 회사는 Item 7.01 및 Exhibit 99.1의 자료가 제출되는 것이며 Exchange Act의 섹션 18에 따라 제출된 것으로 간주되지 않으며, 향후 제출에서 명시적으로 명시된 경우를 제외하고 참조로 통합되지 않는다고 밝힙니다.

대표자들은 때때로 투자자들과의 회의에서 업데이트된 발표를 사용할 수 있습니다. 이 제출은 정보 제공용 Reg FD 업데이트이며 거래나 재무 결과를 발표하지 않습니다.

Sagimet Biosciences (SGMT) a fourni une présentation mise à jour pour les investisseurs en tant qu'Exhibit 99.1 d'un Form 8-K. La société déclare que les matériaux contenus dans l'Item 7.01 et l'Exhibit 99.1 sont fournis et ne sont pas déposés en vertu de la Section 18 de la Exchange Act, ni incorporés par référence sauf indication expresse dans un dépôt futur.

Les représentants peuvent utiliser la présentation mise à jour lors de réunions avec des investisseurs de temps à autre. Le dépôt est une mise à jour informative Reg FD et n'annonce aucune transaction ni résultats financiers.

Sagimet Biosciences (SGMT) hat eine aktualisierte Investorenpräsentation als Exhibit 99.1 zu einem Form 8-K bereitgestellt. Das Unternehmen erklärt, dass die Materialien in Item 7.01 und Exhibit 99.1 bereitgestellt werden und nicht gemäß Abschnitt 18 des Exchange Act eingereicht werden, noch durch Verweis aufgenommen, es sei denn ausdrücklich in einer zukünftigen Einreichung festgelegt.

Vertreter können die aktualisierte Präsentation in Meetings mit Investoren von Zeit zu Zeit verwenden. Die Einreichung ist ein informativer Reg-FD-Update und kündigt weder eine Transaktion noch Ergebnisse an.

Sagimet Biosciences (SGMT) قد زودت المستثمرين بعرض تقديمي محدث كمعروض 99.1 إلى نموذج 8-K. وتذكر الشركة أن المواد الواردة في البند 7.01 والمعروض 99.1 يتم تقديمها وليست معتمدة كمرجع وفقاً للقسم 18 من قانون التبادل، ولا يتم إدراجها بالمرجع إلا كما هو مذكور صراحة في ملف مستقبلي.

يمكن للممثلين استخدام العرض المحدث في الاجتماعات مع المستثمرين من وقت لآخر. هذا الإيداع هو تحديث معلوماتي Reg FD ولا يعلن عن صفقة أو نتائج مالية.

Sagimet Biosciences (SGMT) 已提供更新的投资者演示文稿,作为 Exhibit 99.1 附在 Form 8-K 上。公司声明,Item 7.01 和 Exhibit 99.1 的材料被提供,并且不被视为根据交易法第18条而备案,亦不得通过引用纳入,除非在未来的提交中明确规定。

代表们可在不时的投资者会议中使用更新后的演示文稿。该提交属于信息性 Reg FD 更新,并不宣布交易或财务业绩。

Positive
  • None.
Negative
  • None.

Sagimet Biosciences (SGMT) ha fornito una presentazione aggiornata agli investitori come Exhibit 99.1 in un Form 8-K. L'azienda afferma che i materiali in Item 7.01 e Exhibit 99.1 sono forniti e non considerati depositati ai sensi della Sezione 18 della Exchange Act, né incorporati per riferimento se non espressamente indicato in un futuro deposito.

I rappresentanti possono utilizzare la presentazione aggiornata durante incontri con gli investitori di volta in volta. Il deposito è un aggiornamento informativo Reg FD e non annuncia una transazione o risultati finanziari.

Sagimet Biosciences (SGMT) proporcionó una presentación para inversores actualizada como el Exhibit 99.1 a un Formulario 8-K. La compañía declara que los materiales en el Item 7.01 y Exhibit 99.1 se están proporcionando y no se consideran presentados conforme a la Sección 18 de la Exchange Act, ni incorporados por referencia a menos que se indique expresamente en un depósito futuro.

Los representantes pueden utilizar la presentación actualizada en reuniones con inversores de vez en cuando. El depósito es una actualización informativa Reg FD y no anuncia una transacción ni resultados financieros.

Sagimet Biosciences (SGMT)는 Form 8-K의 Exhibit 99.1로 업데이트된 투자자 발표를 제공했습니다. 회사는 Item 7.01 및 Exhibit 99.1의 자료가 제출되는 것이며 Exchange Act의 섹션 18에 따라 제출된 것으로 간주되지 않으며, 향후 제출에서 명시적으로 명시된 경우를 제외하고 참조로 통합되지 않는다고 밝힙니다.

대표자들은 때때로 투자자들과의 회의에서 업데이트된 발표를 사용할 수 있습니다. 이 제출은 정보 제공용 Reg FD 업데이트이며 거래나 재무 결과를 발표하지 않습니다.

Sagimet Biosciences (SGMT) a fourni une présentation mise à jour pour les investisseurs en tant qu'Exhibit 99.1 d'un Form 8-K. La société déclare que les matériaux contenus dans l'Item 7.01 et l'Exhibit 99.1 sont fournis et ne sont pas déposés en vertu de la Section 18 de la Exchange Act, ni incorporés par référence sauf indication expresse dans un dépôt futur.

Les représentants peuvent utiliser la présentation mise à jour lors de réunions avec des investisseurs de temps à autre. Le dépôt est une mise à jour informative Reg FD et n'annonce aucune transaction ni résultats financiers.

Sagimet Biosciences (SGMT) hat eine aktualisierte Investorenpräsentation als Exhibit 99.1 zu einem Form 8-K bereitgestellt. Das Unternehmen erklärt, dass die Materialien in Item 7.01 und Exhibit 99.1 bereitgestellt werden und nicht gemäß Abschnitt 18 des Exchange Act eingereicht werden, noch durch Verweis aufgenommen, es sei denn ausdrücklich in einer zukünftigen Einreichung festgelegt.

Vertreter können die aktualisierte Präsentation in Meetings mit Investoren von Zeit zu Zeit verwenden. Die Einreichung ist ein informativer Reg-FD-Update und kündigt weder eine Transaktion noch Ergebnisse an.

false 0001400118 0001400118 2025-10-23 2025-10-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 23, 2025

 

 

SAGIMET BIOSCIENCES INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware 001-41742 20-5991472
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

Sagimet Biosciences Inc.

155 Bovet Road, Suite 303,

San Mateo, California 94402

(Address of principal executive offices, including zip code)

 

(650) 561-8600

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trade
Symbol(s)
Name of each exchange on which registered
Series A Common Stock, $0.0001 par value per share SGMT The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On October 23, 2025, Sagimet Biosciences Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

 

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall Exhibit 99.1 furnished herewith be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit 
No.
  Document
99.1   Investor Presentation of Sagimet Biosciences Inc., dated October 23, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Sagimet Biosciences Inc.
     
Date: October 23, 2025 By: /s/ David Happel
    David Happel
    Chief Executive Officer

 

 

 

FAQ

What did Sagimet Biosciences (SGMT) disclose in this Form 8-K?

The company furnished an updated investor presentation, attached as Exhibit 99.1.

Is the Sagimet (SGMT) investor presentation considered filed with the SEC?

No. The information in Item 7.01 and Exhibit 99.1 is furnished, not filed, under the Exchange Act.

How will Sagimet (SGMT) use the updated investor presentation?

Company representatives will use it in meetings with investors from time to time.

What is the date of the updated investor presentation for SGMT?

The investor presentation is dated October 23, 2025.

Which exhibit contains the Sagimet (SGMT) investor presentation?

It is included as Exhibit 99.1 to the Form 8-K.

On which exchange does Sagimet (SGMT) trade and under what symbol?

Sagimet’s Series A Common Stock trades on The Nasdaq Global Market under SGMT.
Sagimet Biosciences Inc.

NASDAQ:SGMT

SGMT Rankings

SGMT Latest News

SGMT Latest SEC Filings

SGMT Stock Data

253.02M
36.10M
9.81%
29.21%
7.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN MATEO